Methods for the treatment and prevention of liver disease
US9981048B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 11, 2014 |
| Grant date | May 29, 2018 |
| Priority date | — |
| Expiry date | Jan 27, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2750/14171
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The presently disclosed invention is directed to the discovery that hepatocyte nuclear factor 4 alpha (HNF4α; also known as NR2A1), a transcription factor, reverses hepatocyte dysfunction in an animal model of cirrhosis, resulting in improvement in hepatic function, treatment of cirrhosis, and prolonged survival.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.